The Dupixent Lawsuit in Short
Yes, there are filed Dupixent lawsuits. Patients and families claim that Dupixent (dupilumab), a biologic injection developed by Regeneron and Sanofi, caused or accelerated cutaneous T-cell lymphoma (CTCL), a cancer of white blood cells that starts in the skin. On June 4, 2026, a panel of federal judges centralized the federal cases as In re Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180, in the District of New Jersey.
As of November 2, 2026, the panel reported 40 cases pending in the MDL. There is no settlement, no verdict and no claim form as of November 20, 2026, and no court has found that Dupixent causes lymphoma. These are personal injury lawsuits, not a class action, so each plaintiff must prove their own case.
What the Dupixent Lymphoma Lawsuits Claim
According to the transfer order, most plaintiffs used Dupixent for atopic dermatitis, the most common form of eczema, and were later diagnosed with CTCL. Others are spouses or survivors of Dupixent users. Each alleges that Dupixent caused CTCL or made an existing CTCL progress faster.
A December 16, 2025 complaint filed in federal court in Chicago, Walsh v. Regeneron Pharmaceuticals, Inc., No. 1:25-cv-15265, shows the typical claims. It alleges the companies knew or should have known about the risk, that the U.S. label makes no mention of it, and that they could have added a warning. It brings claims for failure to warn, negligence, negligent misrepresentation and breach of warranty. These are allegations that have not been proven.
We found no public statement from Regeneron or Sanofi responding to the merits of the lymphoma claims. In the MDL proceedings, the companies asked the court to limit the cases to CTCL rather than all T-cell lymphomas.
The Federal MDL in New Jersey
Plaintiffs asked the Judicial Panel on Multidistrict Litigation to centralize the cases in February 2026, proposing the Northern District of Georgia. Regeneron, Sanofi-Aventis U.S. LLC and Genzyme Corporation proposed the Southern District of New York or a Florida court. The panel chose New Jersey, where Sanofi’s U.S. business is based, and assigned the cases to U.S. District Judge Zahid N. Quraishi in Trenton.
- February 13, 2026: motion to create the MDL filed
- June 4, 2026: transfer order creates MDL No. 3180 with 15 cases from 12 districts
- June 11, 2026: Initial Procedure Order No. 1 consolidates the cases for pretrial purposes
- October 1, 2026: initial management conference set in Trenton
- November 2, 2026: 40 cases pending, 41 filed in total
The panel left one fight open. Plaintiffs want the MDL to include other T-cell lymphomas, such as peripheral T-cell lymphoma, while the companies want it limited to CTCL. The panel said it could decide later whether to expand the MDL. The official transfer order is posted at jpml.uscourts.gov.
MDL does not mean class action
An MDL groups separate injury lawsuits before one judge for pretrial work such as discovery and expert rulings. Each case keeps its own claims, and there is no automatic payment to Dupixent users.
What the FDA and the Research Say
The FDA first approved Dupixent in 2017. It is now approved for moderate-to-severe atopic dermatitis in patients 6 months and older, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, COPD, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis. The current U.S. label, revised in April 2026, does not mention lymphoma or other cancers.
In its list of potential safety signals for October to December 2024, the FDA named cutaneous T-cell lymphoma as a potential signal for Dupixent. As of March 6, 2025, the agency said it “is evaluating the need for regulatory action.” A potential signal is not a finding that the drug causes the condition, and we found no later FDA action.
A 2024 study in Dermatologic Therapy compared 19,612 eczema patients treated with dupilumab with the same number of matched untreated patients. It found 55 CTCL cases in the treated group and 12 in the untreated group, a relative risk of 4.59, with most cases in the first year. The authors noted limits, including the retrospective design and reliance on billing codes, and called for prospective studies. Whether the science shows a causal link between Dupixent and CTCL is one of the main common questions the panel identified for the litigation.
Who Qualifies and What Patients Can Do Now
There is nothing to sign up for. No settlement fund, claim form or payout exists. The cases filed so far involve people diagnosed with CTCL or a related T-cell lymphoma after using Dupixent, and their families. Anyone else who used the drug has no claim tied to these lawsuits.
- Do not stop or change a prescribed medicine without talking to your doctor.
- Report suspected side effects to the FDA’s MedWatch program.
- Keep pharmacy and treatment records if you were diagnosed with a T-cell lymphoma after using Dupixent.
- Be aware that injury lawsuits have filing deadlines set by state law.
Our guide on how long lawsuit settlements take explains why drug injury cases often take years. We list court-approved payouts on our settlements page.
Other Dupixent Lawsuits
Regeneron also sued Sanofi in federal court in New York in November 2024 over their Dupixent partnership. BioSpace reported that Regeneron alleges Sanofi withheld pharmacy benefit manager rebate agreements and blocked a full audit of Dupixent sales. Sanofi said it is “in full compliance” with the agreement. That is a business dispute between the two companies and does not involve patients.
We found no consumer class action or securities class action over Dupixent. The lymphoma claims are separate from other drug cases on this site, such as the Tepezza hearing loss MDL.
What Happens Next
The next steps in MDL No. 3180 are the appointment of lawyers to lead each side, a schedule for master pleadings and discovery, and later expert hearings on whether the science supports a causal link. We have not confirmed what was decided at the October 1, 2026 conference. No bellwether trial dates have been set that we could find, and no settlement talks have been reported.
The panel may also be asked to add cases involving other T-cell lymphomas. We will update this page when the court issues major rulings. Our sourcing standards are on how we verify.
Before You Act
Thinking About Filing a Claim?
Many lawyers in injury and consumer cases work on contingency, taking a share of any recovery. Case costs can be owed separately, so read the written fee agreement before signing; see what lawyers charge. The Lawsuit Watch is not a law firm: we publish explainers, and we do not provide legal advice, representation or referrals. Your state bar directory is the reliable place to find and verify a lawyer.
Sources
Key figures and dates on this page were checked against the sources below on November 20, 2026. Settlement terms and status can change; confirm the current position with the court or the official settlement administrator before relying on it. How we verify.
- JPML transfer order, In re Dupixent (Dupilumab) Products Liability Litigation, MDL No. 3180 (June 4, 2026)
- JPML report: pending MDLs by actions pending (Nov. 2, 2026)
- FDA: October to December 2024 potential signals of serious risks
- DailyMed: Dupixent prescribing information
- Mandel et al., Dermatologic Therapy (2024), dupilumab and CTCL cohort study
- BioSpace: Regeneron sues Sanofi over Dupixent pact (Feb. 7, 2025)
Dupixent Lawsuit: The Cutaneous T-Cell Lymphoma Claims and MDL 3180: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
Is there a Dupixent class action lawsuit?
No. The Dupixent lymphoma cases are individual injury lawsuits grouped in a federal MDL, not a class action, and there is no class settlement.
How many Dupixent lawsuits have been filed?
The Judicial Panel on Multidistrict Litigation reported 40 cases pending in MDL No. 3180 as of November 2, 2026, out of 41 filed in total.
Has there been a Dupixent settlement?
No. As of November 20, 2026, there is no settlement, verdict or claim form in the Dupixent lymphoma litigation.
Does Dupixent cause lymphoma?
That has not been established. The FDA listed cutaneous T-cell lymphoma as a potential safety signal in 2025 and said it was evaluating whether action is needed, and the current label does not mention lymphoma.
Who is suing over Dupixent?
Mostly people who used Dupixent for eczema and were later diagnosed with cutaneous T-cell lymphoma, plus spouses and survivors of users. They sued Regeneron, Sanofi-Aventis U.S. and Genzyme.
Where is the Dupixent MDL?
MDL No. 3180 is in the U.S. District Court for the District of New Jersey before Judge Zahid N. Quraishi.
Legal Disclaimer
This article is general legal information, not legal advice, and does not create an attorney-client relationship. Case status, eligibility criteria, and any amounts described are as reported at the date shown and may change. Consult a licensed attorney in your jurisdiction about your own situation.